Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | MET proto-oncogene, receptor tyrosine kinase | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | plexin a4 | 0.0025 | 1 | 1 |
Schistosoma mansoni | plexin | 0.0012 | 0.2147 | 0.2822 |
Schistosoma mansoni | hypothetical protein | 0.0012 | 0.2147 | 0.2822 |
Onchocerca volvulus | 0.0021 | 0.7608 | 1 | |
Brugia malayi | Plexin repeat family protein | 0.0021 | 0.7608 | 0.7608 |
Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.7608 | 0.7608 |
Loa Loa (eye worm) | plexin A | 0.0025 | 1 | 1 |
Schistosoma mansoni | plexin | 0.0021 | 0.7608 | 1 |
Echinococcus multilocularis | plexin a4 | 0.0025 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.2147 | 0.2147 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 2 nM | BindingDB_Patents: LanthaScreen Assay. The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) using lanthanide chelates to measure interactions between various binding partners. In a TR-FRET kinase assay, a long-lifetime lanthanide donor species is conjugated to an antibody that specifically binds to a phosphorylated product of a kinase reaction that is labeled with a suitable acceptor fluorophore. This antibody-mediated interaction brings the lanthanide donor and the acceptor into proximity such that resonance energy transfer can take place, resulting in a detectable increase in the FRET signal.The kinase reactions were performed in 384 well microtiter plates in a total reaction volume of 10.05 µL. The assay plates were prepared with 0.05 µL per well of test compound in the appropriate test concentration, as described under preparation of compound dilutions. | ChEMBL. | No reference |
IC50 (binding) | = 25000 nM | BindingDB_Patents: Scintillation Proximity Assay (SPA). The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) using lanthanide chelates to measure interactions between various binding partners. In a TR-FRET kinase assay, a long-lifetime lanthanide donor species is conjugated to an antibody that specifically binds to a phosphorylated product of a kinase reaction that is labeled with a suitable acceptor fluorophore. This antibody-mediated interaction brings the lanthanide donor and the acceptor into proximity such that resonance energy transfer can take place, resulting in a detectable increase in the FRET signal.The kinase reactions were performed in 384 well microtiter plates in a total reaction volume of 10.05 µL. The assay plates were prepared with 0.05 µL per well of test compound in the appropriate test concentration, as described under preparation of compound dilutions. | ChEMBL. | No reference |
IC50 (binding) | = 25000 nM | BindingDB_Patents: Scintillation Proximity Assay (SPA). The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) using lanthanide chelates to measure interactions between various binding partners. In a TR-FRET kinase assay, a long-lifetime lanthanide donor species is conjugated to an antibody that specifically binds to a phosphorylated product of a kinase reaction that is labeled with a suitable acceptor fluorophore. This antibody-mediated interaction brings the lanthanide donor and the acceptor into proximity such that resonance energy transfer can take place, resulting in a detectable increase in the FRET signal.The kinase reactions were performed in 384 well microtiter plates in a total reaction volume of 10.05 µL. The assay plates were prepared with 0.05 µL per well of test compound in the appropriate test concentration, as described under preparation of compound dilutions. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.